Skin disease models for testing local effects of nanomedicines.

PRISCILA SCHILRREFF

Conferencia; 1st Zooming into preclinical nanomedicines in the era Covid19-.; 2020

Preclinical assessment of novel nanomedicines therapies to fight skin diseases requires models that reflect the human physiology and immune response. The lack of similarity between human and animal skin and the growing ethical concerns in the use of animal models have boosted the search for novel realistic threedimensional skin models. The potential use of nanocarriers for dermal application has been widely explored, as they promise high drug concentrations in the skin, low systemic adverse effects, controlled and targeted drug deliveryand the achievement of higher therapeutic effectscompared with conventional topical preparations. First, using tecto-dendrimers as an example, this work will show a detailed analysis ofthe (semi-) quantitative evaluation of skin nanocarrier penetration on skin ex vivo, threedimensional skin models and nonmelanoma skin cancer models (NMSC). On the other hand, the development of a biologically relevant and unique experimental human cell-based platform of impaired wound healing for the future evaluation of new effective topical treatments in cutaneous leishmaniasis related ulceration will also be shown. Taken together, this work will provide new biological insights into the microenvironment ofskin disease models and their interaction with novel nanomedicines for the evaluation of the local effects of new drug delivery systems.